Compare · CAH vs COR
CAH vs COR
Side-by-side comparison of Cardinal Health Inc. (CAH) and Cencora Inc. (COR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CAH and COR operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- COR is the larger of the two at $65.15B, about 1.1x CAH ($58.75B).
- Over the past year, CAH is up 61.6% and COR is up 4.1% - CAH leads by 57.5 points.
- COR has been more active in the news (4 items in the past 4 weeks vs 3 for CAH).
- Both have 25 recent analyst ratings on file.
- Company
- Cardinal Health Inc.
- Cencora Inc.
- Price
- $254.13+0.17%
- $340.81-0.14%
- Market cap
- $58.75B
- $65.15B
- 1M return
- +12.23%
- +10.16%
- 1Y return
- +61.57%
- +4.06%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 3
- 4
- Recent ratings
- 25
- 25
Cardinal Health Inc.
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.
Cencora Inc.
CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options  all of which leads to a best-in-class customer experience and lasting relationships.
Latest CAH
- Cardinal Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health
- Cardinal Health to Announce First-Quarter Results for Fiscal Year 2027 on November 5
- SEC Form DEF 14A filed by Cardinal Health Inc.
- SEC Form DEFA14A filed by Cardinal Health Inc.
- Chief Accounting Officer Scherer Mary C. sold $546,473 worth of shares (2,302 units at $237.39), decreasing direct ownership by 45% to 2,811 units (SEC Form 4)
- Chief Executive Officer Hollar Jason M. sold $29,375,516 worth of shares (124,529 units at $235.89), decreasing direct ownership by 40% to 190,603 units (SEC Form 4)
- CEO, GMPD Segment Mason Stephen M sold $8,274,117 worth of shares (35,000 units at $236.40), decreasing direct ownership by 66% to 18,061 units (SEC Form 4)
- CEO, PSS Segment Weitzman Deborah sold $1,731,524 worth of shares (7,354 units at $235.45), decreasing direct ownership by 9% to 77,901 units (SEC Form 4)
- Chief Financial Officer Alt Aaron E sold $9,926,140 worth of shares (42,000 units at $236.34), decreasing direct ownership by 67% to 20,495 units (SEC Form 4)
Latest COR
- SEC Form 4 filed by Cencora Inc.
- SEC Form 4 filed by Cencora Inc.
- Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release
- New insider Sanchez Robert E claimed ownership of 197 shares (SEC Form 3)
- Cencora Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Cencora Elects Robert E. Sanchez to Its Board of Directors
- Director Greenberg Lon R sold $411,264 worth of shares (1,280 units at $321.30), decreasing direct ownership by 7% to 17,128 units (SEC Form 4)
- SVP & Chief Accounting Officer Krikorian Lazarus sold $321,080 worth of shares (985 units at $325.97) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 16,169 units (SEC Form 4)
- Executive Vice President Campbell Elizabeth S sold $3,662,663 worth of shares (11,300 units at $324.12), decreasing direct ownership by 37% to 19,455 units (SEC Form 4)
- RBC Capital Mkts initiated coverage on Cencora with a new price target